Company profile

Jasper Therapeutics, Inc. Insider Trading

JSPR

Every SEC Form 4 insider trading filing for Jasper Therapeutics, Inc. (JSPR) since April 2023 — open-market buys and sells by directors and officers, option exercises, and cluster activity, updated as each filing is reported to the SEC. Why 2023?

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
CIK
0001788028
Filings
74
Insiders
39
Last filing
2026-07-31

Activity summary

Recent insider activity is bullish. Over the last 30 days, 5 insiders purchased shares. Buying was led by Wiggans Thomas G.

Three year balance

Buy and sell value by quarter, Q2 23 to Q3 26. Jasper Therapeutics, Inc. insiders are net buyers across the period shown.

Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q1 26Q3 26

Bars below the rule are sales, above are purchases. Largest quarter on the chart is $7.0M.

90 day insight

Over the last 90 days, Jasper Therapeutics, Inc. insiders bought $0 across 8 transactions with no open-market sales.

  • Most active insider: Crutcher Patrick J with 3 transactions totaling $0.

Activity skews bullish — buys outpace sales.

Insider Transactions

Sourced from SEC EDGAR Form 4 filings. Updated hourly.

DateInsiderCompanyTypeSharesPriceValue
Jul 31, 2026Wiggans Thomas GJSPR
Award
7,500
Jul 31, 2026Emster Kurt VonJSPR
Award
7,500
Jul 31, 2026Lucas SvetlanaJSPR
Award
7,500
Jul 31, 2026Shizuru Judith AnneJSPR
Award
7,500
Jul 31, 2026Crutcher Patrick JJSPR
Award
7,500

45 more transactions hidden

Free account · No credit card required

Building something? Get API access →

Query this yourself

The same rows, over the API.

curl "https://api.form4api.com/v1/transactions?ticker=JSPR" \
  -H "X-Api-Key: $KEY"
Get a key

Top insiders

By total value filed.

Shizuru Judith AnneDirector1 filing+$100K
Wiggans Thomas GChief Executive Officer1 filing+$100K
Martell RonPresident, CEO and Director1 filing+$100K
Mahal Jeetinder SinghSee Remarks6 filings$42K
Lucas SvetlanaChief Business Officer1 filing+$49K

Institutional Ownership

Top 13F-HR holders of Jasper Therapeutics, Inc. as of 2026-06-30

— stable
Total reported AUM
$544,814
QoQ change
Reporting period
2026-06-30
#1
Carlyle Group Inc.
CIK 0001527166
$448,866
1.1M shares
#2
BlackRock, Inc.
CIK 0002012383
$71,413
170K shares
#3
State Street Corp
CIK 0000093751
$18,818
45K shares

Data source: quarterly 13F-HR filings — institutional holders report positions within 45 days of quarter end. Joined with insider activity above — see who's loading up institutionally while insiders are trading. Full 13F-HR API →